Business Context and Reporting Period
Company: Medifast, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Medifast manufactures and markets weight management products and programs, including the "Take Shape for Life" division. The company operates through direct sales to consumers and a sales network.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Revenue | $10,985,000 | $29,865,000 |
| Gross Profit | $8,310,000 | $22,495,000 |
| Gross Margin | 75.6% | 75.3% |
| Operating Income | $1,266,000 | $3,332,000 |
| Net Income | $617,000 | $1,878,000 |
| Net Income Attributable to Common Shareholders | $607,000 | $1,587,000 |
| Diluted EPS | $0.05 | $0.13 |
| Cash and Cash Equivalents | $2,641,000 | $2,641,000 |
| Working Capital | $9,627,000 | $9,627,000 |
| Total Debt (Current + Long-term) | $5,318,000 | $5,318,000 |
Note: Total Debt includes Line of Credit ($642,000), Current maturities of long-term debt ($556,000), and Long-term debt ($4,120,000).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 51% ($3.7M) for the quarter and 39% ($8.4M) for the nine-month period compared to 2004. Growth was driven by direct sales campaigns and expansion of the "Take Shape for Life" sales network.
- Profitability: Net income attributable to common shareholders increased 55% for the quarter ($607k vs $391k) but decreased 6% for the nine-month period ($1.587M vs $1.694M) due to preferred stock dividends and increased share count.
- Expenses: Cost of sales increased 42% and Selling, General, and Administrative (SG&A) expenses increased 39% year-over-year for the nine-month period, primarily due to higher advertising spend and increased sales volume.
- Liquidity: Cash and cash equivalents increased significantly from $612,000 at year-end 2004 to $2,641,000 at September 30, 2005. Net cash provided by operating activities was $2.94M for the nine months ended September 30, 2005, compared to a use of $1.54M in the prior year.
- Capital Structure: All Series B and Series C Convertible Preferred Stock were converted to common stock as of September 30, 2005. This eliminated future preferred dividends but increased the weighted average shares outstanding, impacting EPS.
Outlook, Risks, and Management Commentary
- Seasonality: Management notes that traditional seasonality (weak sales in Nov/Dec, strong in Jan/Feb) is decreasing as consumers associate the products with overall health rather than just seasonal dieting.
- Strategic Initiatives: The company is expanding its sales network and increasing advertising spend across print, mail, web, and television. A new license agreement with Game Time, LLC (Ray Lewis) was signed for sports performance shakes.
- Accounting Changes: The company is evaluating the impact of FAS 123R (Share-Based Payment), effective January 1, 2006, which will require expensing stock-based compensation. Pro forma EPS for the nine months ended Sep 30, 2005, would have been $0.10 diluted under this standard.
- Legal Contingencies:
- Donavin Litigation: A suit alleging Vitamin D3 violations in meal replacement bars is being dismissed due to lack of merit.
- Bankruptcy Dispute: A dispute exists regarding shares allegedly transferred by a former consultant to avoid bankruptcy proceedings. The company contests the claim and expects the shares to be returned to the estate.
Investor Verification Checklist
- Verify the sustainability of the 39% revenue growth rate given the significant increase in SG&A and advertising costs.
- Confirm the impact of the full conversion of Series B and C preferred stock on future earnings per share and dividend obligations.
- Assess the potential financial impact of adopting FAS 123R in 2006 on reported net income.
- Monitor the resolution of the bankruptcy estate dispute regarding the former consultant's shares.
- Review the effectiveness of the new Ray Lewis product line and sales network expansion in driving future margins.